Sign in
Taking peopleNo phase

Blood cell markers in primary and secondary antiphospholipid syndrome

Compares blood cell markers in adults with primary versus secondary antiphospholipid syndrome.

Key facts

Who runs it
New Valley University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Status
Recruiting
People taking part
150 people, planned
Started
27 Nov 2025
Expected to end
30 Jun 2027
Type of study
Observational, 2 groups
Treatments tested
  • • Complete blood count , MPV
  • Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:
  • Antiphospholipid antibody profile
Record updated
31 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with antiphospholipid syndrome (APS), either primary or secondary. It compares simple blood count markers between these two groups.

Age
18 years and older
Sex
All sexes
Disease stage
APS diagnosed by the updated Sydney classification criteria. People must have had blood clots and/or pregnancy problems. Both primary APS and secondary APS can join.
Earlier treatment
People cannot join after a recent blood transfusion. They also cannot join if they take medicines that change platelets, other than APS treatments.
Biomarker or test result
Antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant) found persistently, for ≥12 weeks.

Main reasons for not taking part

  • Current infection or inflammation not caused by APS
  • Blood cancers or other blood disorders
  • Recent blood transfusion
  • Platelet-altering medicines other than APS treatments

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Adults (age ≥18 years)
  • Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)

Who cannot take part

  • Current infection or inflammatory condition unrelated to APS
  • Hematological malignancies or other blood disorders
  • Recent blood transfusion or platelet-altering medications other than APS treatments

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations

The 2 groups in the trial

  • 1

    Primary APS

    Treatment: • Complete blood count , MPV, Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:, and Antiphospholipid antibody profile

  • 2

    secondary APS

    Treatment: • Complete blood count , MPV, Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:, and Antiphospholipid antibody profile

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparative Analysis of Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Plain-language title
Blood cell markers in primary and secondary antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
31 July 2026